NaDC-3 Activators
The activators of NaDC-3 are diverse, influencing this sodium-coupled dicarboxylate transporter in various ways, primarily by modulating the sodium gradient, substrate availability, and cellular metabolic status. Lithium Chloride, through its impact on ionic balances, can enhance NaDC-3 activity by potentially affecting the sodium gradient essential for its transport function. Short-chain fatty acids like Valproic Acid might interact with NaDC-3, potentially enhancing its activity by increasing the availability of substrates for transport. Direct substrates of NaDC-3, such as Citric Acid, Malic Acid, Succinic Acid, and Alpha-Ketoglutaric Acid, can directly enhance its transport activity by serving as substrates, facilitating the movement of dicarboxylates across cellular membranes.
Diuretics like Furosemide, Hydrochlorothiazide, and Spironolactone, although primarily acting on renal sodium handling, can indirectly influence NaDC-3 activity by altering the sodium gradient, a critical factor for NaDC-3 function. Insulin plays a role in enhancing NaDC-3 activity by modulating cellular glucose uptake, which indirectly affects the cellular energy status and thus NaDC-3's function. Similarly, antidiabetic drugs like Metformin and Pioglitazone, by influencing cellular energy metabolism and insulin sensitivity, can indirectly impact NaDC-3's dicarboxylate transport function. Collectively, these activators demonstrate the complex regulation of NaDC-3, highlighting its integral role in cellular transport mechanisms and metabolic processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride may enhance NaDC-3 activity by influencing ionic balances in cells, potentially affecting the sodium gradient, which is crucial for NaDC-3's sodium-coupled dicarboxylate transport function. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid, as a short-chain fatty acid, might interact with NaDC-3, potentially enhancing its dicarboxylate transport activity by affecting substrate availability. | ||||||
Citric Acid, Anhydrous | 77-92-9 | sc-211113 sc-211113A sc-211113B sc-211113C sc-211113D | 500 g 1 kg 5 kg 10 kg 25 kg | $50.00 $110.00 $145.00 $248.00 $598.00 | 1 | |
Citric Acid, a dicarboxylate, can directly enhance NaDC-3 activity by acting as a substrate, thus potentially increasing dicarboxylate transport across cell membranes. | ||||||
Malic acid | 6915-15-7 | sc-257687 | 100 g | $130.00 | 2 | |
Malic Acid, another dicarboxylate, can serve as a substrate for NaDC-3, potentially enhancing its transport activity across cellular membranes. | ||||||
Succinic acid | 110-15-6 | sc-212961B sc-212961 sc-212961A | 25 g 500 g 1 kg | $45.00 $75.00 $133.00 | ||
Succinic Acid, as a substrate for NaDC-3, can directly enhance its transport activity, aiding in the movement of dicarboxylates across cell membranes. | ||||||
α-Ketoglutaric Acid | 328-50-7 | sc-208504 sc-208504A sc-208504B sc-208504C sc-208504D sc-208504E sc-208504F | 25 g 100 g 250 g 500 g 1 kg 5 kg 16 kg | $33.00 $43.00 $63.00 $110.00 $188.00 $738.00 $2091.00 | 2 | |
Alpha-Ketoglutaric Acid, a key dicarboxylate in the Krebs cycle, may enhance NaDC-3 activity by serving as a substrate, facilitating its transport function. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
Furosemide, a loop diuretic, may indirectly enhance NaDC-3 activity by altering renal sodium handling, which could affect the sodium gradient critical for NaDC-3 function. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin can enhance NaDC-3 activity by modulating cellular uptake of glucose, which can indirectly affect cellular energy status and consequently NaDC-3's transport function. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin can influence NaDC-3 activity indirectly by altering cellular energy metabolism, potentially impacting NaDC-3's dicarboxylate transport function. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, a thiazolidinedione, may enhance NaDC-3 activity by affecting insulin sensitivity and glucose metabolism, indirectly influencing NaDC-3's function in cells. | ||||||